Skip to main content
. 2022 Dec 15;108(7):1886–1899. doi: 10.3324/haematol.2022.281444

Figure 6.

Figure 6.

Combination treatment with CCRL2 knockdown and azacitidine leads to MDS-L growth suppression in NSGS mice. (A) Monitoring the bioluminescence signal showed that NSGS mice engrafted with MDS-L cells transduced with shCCRL2 lentivirus treated with intravenous azacitidine (2.5 mg/kg/day every 5 days for 5 doses) showed the smallest disease growth compared to mice engrafted with MDS-L cells transduced with shControl lentivirus and treated with dimethylsulfoxide (DMSO) or azacitidine and mice engrafted with MDS-L cells transduced with shCCRL2 lentivirus and treated with DMSO. (B) Mice engrafted with MDS-L cells transduced with shCCRL2 and treated with azacitidine had lower disease burden in their bone marrow based on the percentage of human CD45 (hCD45+%) cells compared to mice engrafted with shControl transduced cells and treated with azacitidine (P=0.004) and mice engrafted with shCCRL2 transduced cells and treated with DMSO (P=0.008). AZA: azacitidine.